myLaurel

myLaurel is a tech-enabled medical group that delivers on-demand acute and transitional medical care in the home to frail, elderly and medically complex patients. Its stated aim is to help patients avoid the conventional path of ambulance transport, emergency department visit, hospital admission and nursing facility stay, while freeing inpatient capacity for the health systems it serves. The company describes a hybrid model in which trained field responders, nurse practitioners and care managers provide hands-on care in the home, supported in real time by emergency and internal medicine physicians via video, together with diagnostics and therapies delivered at the bedside.

Patient-facing services include in-home urgent and acute care for non-emergency conditions (typically reached in under 90 minutes), in-home blood tests and imaging, IV fluids and medications, breathing treatments, catheter management and cardiac monitoring, plus telehealth visits and follow-up over a 7- to 30-day period after the initial visit. The company also supports hospital-to-home transitions, including medication reconciliation and communication with primary care physicians, and helps connect eligible members to health plan benefits such as transportation, durable medical equipment and lower-cost medications. Free translation services in 300 languages, including American Sign Language, are offered. Referrals come from physicians, care managers or health plans rather than direct patient request, and myLaurel positions itself as complementary to, not a replacement for, a patient's primary care physician.

The company's signature offering is its Acute Care at Home program, developed jointly with Ochsner Health in 2024. myLaurel also cites work with Maimonides Health and University Medical Center New Orleans, and operates a compliance and patient-rights function including participation in New York's Healthix health information exchange.

Founding story

The founding team states it created myLaurel to advance access to care for high-risk patients and to deliver care models for patients and care teams, drawing on a group of clinicians, technologists and healthcare operators who had previously built in-home care models.

Business model

myLaurel contracts with health systems, provider groups and health plans, which refer eligible patients into its in-home acute and transitional care programs. The company states that it puts its fees at risk against agreed outcomes, aligning financial risk with clinical results for partners. Patient cost-sharing varies by service received and insurance coverage, with some services provided at no cost to the patient.

Traction

myLaurel reported a record 2024 and a 4x year-over-year increase in new patient volume and revenue in the first quarter of 2025. Company- and partner-reported outcome figures include a 49% reduction in 30-day readmissions, 33% lower emergency department utilization, roughly 3,000+ bed days saved per hospital annually enabling over 640 additional acute inpatient admissions, an average 1.5-day length-of-stay reduction, 3:1+ ROI within the first 90 days, and a patient Net Promoter Score of 96-97. In its Ochsner program, the companies reported that more than 90% of initial patient admissions were prevented.

Latest developments

In April 2025 myLaurel and Ochsner Health disclosed plans to expand the Acute Care at Home program to additional Ochsner hospital locations during the year and to widen patient eligibility. In June 2025 the company announced a $12 million initial closing led by Deerfield Management and GV, intended to fund expansion with Ochsner and new health system clients. The company was subsequently named to Fast Company's 2026 Most Innovative Companies list, ranking in the top five of its category.